These findings suggest that successful treatment of ICIs requires tumor antigen release, an important part of the cancer-immunity cycle [21], which is elicited by cytotoxic treatments such as chemotherapy or irradiation for HER2-positive tumors. This evidence concerns the gene ERBB2 and neoplasm.